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Animalmodels of critical illness are vital in biomedical research.They provide possibilities for the investigation of pathophysiologi-
cal processes thatmaynot otherwise be possible in humans. In order to be clinically applicable, themodel should simulate the critical
care situation realistically, including anaesthesia, monitoring, sampling, utilising appropriate personnel skill mix, and therapeutic
interventions. There are limited data documenting the constitution of ideal technologically advanced large animal critical care
practices and all the processes of the animal model. In this paper, we describe the procedure of animal preparation, anaesthesia
induction and maintenance, physiologic monitoring, data capture, point-of-care technology, and animal aftercare that has been
successfully used to study several novel ovine models of critical illness. The relevant investigations are on respiratory failure due to
smoke inhalation, transfusion related acute lung injury, endotoxin-induced proteogenomic alterations, haemorrhagic shock, septic
shock, brain death, cerebral microcirculation, and artificial heart studies. We have demonstrated the functionality of monitoring
practices during anaesthesia required to provide a platform for undertaking systematic investigations in complex ovine models of
critical illness.
1. Introduction
Optimal management of the critically ill is the goal for ongo-
ing research utilising clinically relevant animal models. The
body size and close similarities between sheep and human
pulmonary anatomy, physiology, and immunology make
sheep a suitable species for studying pathologies afflicting
humans [1–3]. In comparison, swine also offer considerable
advantages over other large animal models in biomedical
research for the same or more reasons as sheep and ease
of management [4–6]. Anaesthesia is a requirement during
interventions in animal research to minimise or eliminate
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the experimental induction of pain. Optimal anaesthesia
and analgesia need to be titrated to the individual animal
under close monitoring and supervision aided by the use of
patient monitors, data capturing devices, and patient point-
of-care technology. Patient monitors are designed to aid in
determining priorities for care and are not meant to replace
the clinician [7–9] at the tableside. They provide an avenue
for recording significant events to enhance the recognition of
trends in important physiological variables [9–12]. Complex
experiments using ovine models therefore necessitate access
to a well-equipped theatre with advanced organ system
monitoring and point-of-care technology that allows real-
time tailoring of therapy and standardisation of anaesthesia
and critical care practices. Additionally, appropriately trained
researchers with a thorough understanding of the use and
interpretation of these systems and of ovine physiology are
essential.
Currently, there are variedmethodologies of ovine anaes-
thesia, monitoring, organ support, and point-of-care devices
in use in large animal intensive care units (ICUs) and research
facilities around the world. To date, however, there are
limited studies that describe in detail sheep anaesthesia and
monitoring practices in biomedical research establishments
with modern large animal ICUs. The aim of this paper is to
provide an overview of anaesthesia and monitoring practices
used in sheep in comparison with a detailed description
of the procedure of animal preparation, anaesthesia and
monitoring, critical care, data capture, and point-of-care
technology developed by our research group on several
validated ovinemodels (Table 1). It is expected that this paper
will provide a foundation for comparison of the available
ICU monitoring technology for large animal experimental
models and will set an example of recognising the available
anaesthetics and standards of devices currently marketed for
use in large animal models of intensive care.
2. Overview of Anaesthesia and Monitoring
Practices for Ovine Models
Reports from the past ten years show that there were con-
siderable variations in anaesthesia and monitoring practices
in sheep utilised in biomedical research [2, 17, 29–76].
Ketamine was the most commonly used induction agent
followed by thiopentone. Only a few studies used alfaxalone
for induction of anaesthesia [2, 17, 31, 76]. For maintenance
of anaesthesia, halothane in O
2
was the most commonly
used agent followed by isoflurane in O
2
. A limited number
of studies used alfaxalone for maintenance of anaesthesia
[2, 17, 76]. Female sheep of the Merino breed were used in
most of the experiments probably because of their docile
nature and relative availability compared to males. While
it is difficult to parse out the rationale for the various
alternative approaches for ovine anaesthesia and monitoring
in many published studies, the experimental goal, at least
in part, impacts the procedure to be implemented. Several
studies required anaesthesia only during instrumentation,
as subsequent experimental procedures required sheep to
be conscious. In sheep that required assisted ventilation,
the Servo ventilator (model 900C, Siemens-Elena; Solna,
Sweden) was the most commonly used device. In stud-
ies that documented the method of euthanasia of sheep,
the administration of ketamine anaesthesia in combination
with a saturated potassium chloride solution was the most
commonly used approach. Unlike companion and other
laboratory animal anaesthesia, small ruminant anaesthesia
is an area that is still evolving, which may explain the
variability in anaesthesia and monitoring techniques. Fur-
thermore, sheep are not routinely anaesthetised in veterinary
practice; therefore, few anaesthetics or procedures have been
developed specifically for this species. For this reason and
probably because they are food animals, many anaesthetic
drugs are not registered for use in sheep. Several other factors
that may affect the choice of anaesthesia and monitoring
include experience with the species, anaesthetic drug costs
and availability, and monitoring facilities.
There is also considerable diversity in the types of tech-
nological devices used for physiological monitoring during
anaesthesia and equipment used in point-of-care in various
centres that have studied sheep. Some differences of these
devices are notably in the type of physiological monitors,
blood gas analysers, pressure transducers, anaesthetic gas
analysers, blood flow meters, data acquisition recorders,
oximeters, cardiac output monitors, brain monitors, blood
cell counters, protein assayers, and colloid osmometers
(Table 2).
A consideration of all the factors on anaesthetics and
monitoring technology is very helpful for aiding future
investigators in making the appropriate choices for the sort
of gear required for procedures they would like to implement
in their large animal studies.
3. Laboratory Practices for Ovine Models at
the Critical Care Research Group (CCRG) in
Australia
In this section, we describe anaesthesia, critical care and
monitoring practices, data capture, and point-of-care techno-
logical techniques used at a large Australian animal research
laboratory. The CCRG Laboratory has considerable expe-
rience in anaesthetising sheep under ICU conditions and
has developed several validated ovine models. The areas of
discussion are classified into anaesthesia practice, advanced
monitoring, auxiliary life support equipment, and point-of-
care technology. Brief overviews of the relevant ovine models
are also provided.
3.1. Animal Care, Anaesthesia, and Monitoring. Animals are
treated in accordance with the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes
[77]. All studies are registered with institutional Animal
Welfare and Ethics departments and have the Animal Ethics
Committee (AEC) approval fromTheQueenslandUniversity
of Technology (QUT) and The University of Queensland
(UQ). Local guidelines mandate the presence of at least
two trained personnel to be with the animal model at
all times for the duration of a given experiment. This is
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Table 1: Validated ovine models of the Critical Care Research Group (CCRG) in Australia.
Model Total number of sheep required Publications
Extracorporeal membrane oxygenation (ECMO) 72 [2, 13–16]
Transfusion-related acute lung injury (TRALI) 112 [17–20]
Cardiac mechanical assist device project (CMADP) 9 + (ongoing study) [21–24]
Colloids, red cells, aged red cells, sepsis, and haemorrhage (CRASH-S and CRASH-H) 16 + (ongoing study) [20]
Smoke induced acute lung injury (S-ALI) 20 [25]
Brain stem death (BSD) 24 [26, 27]
Intracardiac echocardiography guided transseptal catheterization (ICETSC) 20 + (ongoing study) [28]
Table 2: Technological devices used in anaesthesia and critical care monitoring in biomedical research on ovine models.
Devices Models
Physiological monitors
Mindray 9200 anaesthetic monitor (Mindray, Shenzhen, China) [31]; multichannel Gould polygraph
recorder (Gould, Valley View, OH, USA) [46]; SurgiVet monitor (SurgiVet V9203; Smiths Medical, MA,
USA) [30]; Datex monitor (Datex-Engstrom Compact; Datex-Engstrom Inc., Tewksbury, MA, USA) [50];
System 6, (Triton Technology SD, CA, USA) [52]; haemodynamic monitor (MP150, BIOPAC Systems,
Goleta, CA, USA) [36]; 7830A (Hewlett Packard, Santa Clara, CA, USA)
[35, 41, 44, 45, 54, 56, 65–67, 72–74, 79]; V24C (Philips Medizin Systeme Bo¨blingen, Bo¨blingen, Germany)
[53]; IntelliVue MP50 (Philips Medical Systems, Bo¨blingen, Germany) [49]; V24 and V26 (Philips-Agilent,
Andover, MA, USA) [68]; and OM9 (Electronics for Medicine, Pleasantville, NY, USA) [40, 53, 68, 75].
Blood gas analysers
iSTAT CG4 (Abbott Laboratories, USA) [31]; Radiometer ABL 700 (Radiometer America Inc., OH, USA)
[30]; ABL 700, (Radiometer, Copenhagen, Denmark) [42]; ABL 5 (Radiometer, Copenhagen, Denmark)
[69]; ABL 500 (Radiometer, Westlake, OH, USA) [64]; ABL 800 Flex (Radiometer, Copenhagen,
Denmark) [37]; IL GEM Premier 3000 (IL GEM, GMI, MN, USA) [33, 43, 48]; 1302 IL (Instrumental
Laboratory, Lexington, MA, USA) [38, 68]; IL1600 (Instrumentation Laboratory, Lexington, MA, USA)
[39]; and Synthesis 15 (Instrumentation Laboratories, Lexington, MA, USA)
[35, 41, 44, 45, 54, 56, 65–67, 72–74, 79].
Pressure transducers
Statham pressure transducer (Statham, Oxnard, CA, USA) [46]; pressure transducers (Edwards
Lifesciences LLC, Irvine, CA, USA) [40, 53, 68, 75]; pressure transducer (ITL Healthcare, Australia) [30];
pressure transducer (Medex Medical Ltd., Lancs, UK) [50]; pressure transducer (Vigilance, Edwards
Lifesciences, S.A., Saint-Prex, Switzerland) [50]; pressure transducer PT (COBE, Argon, TX, USA) [69];
PX3X3 (Baxter, Edwards Critical Care Division, Irvine, CA, USA)
[35, 41, 44, 45, 53, 54, 56, 65, 66, 73, 74, 79]; PX-1800 (Baxter, Edwards Critical Care Division, Irvine, CA,
USA) [67, 72]; and PXMK 1590 (Edwards Lifesciences) [49].
Anaesthetic gas analysers
Anaesthetic gas analyser (Datex Capnomac; Datex-Ohmeda, Madison, WI, USA) [46]; Capnomac
(Ultima, Datex-Ohmeda, Helsinki, Finland) [61]; lactate + NO (YSI 2300, OH, USA); nitric oxide monitor
(Micro Medical, ME, USA) [64, 72]; and GEM Premier 3000 (Instrumentation Laboratory, Lexington,
MA, USA) [49].
Blood flow meters
Triton System 6 (model 200, Triton Technology, San Diego, CA, USA) [57, 58]; FBF monitor (model
T201/T206, Transonic Systems, Ithaca, NY, USA) [69]; and T208 Transonic Volume Flow Meter
(Transonic Systems, Ithaca, NY, USA) [53, 68].
Data acquisition and recorders
PowerLab/8SP (ADInstruments, Castle Hill, Australia) [57, 58]; Data Acquisition System (Cornell
University, Ithaca, NY); electronic analog-to-digital converter (NIDAQ, National Instruments, Austin, TX,
USA) [69]; and Chart 5 acquisition software (ADInstruments, Sydney, Australia) [60].
Oximeters
OSM3 Haemoximeter, (Radiometer, Westlake, OH, USA) [64]; Haemoximeter (OSM2, Radiometer) [69];
CO-Oximeter IL482 (Instrumentation Laboratory) [35, 41, 44, 45, 54, 56, 65–67, 72–74, 79]; FiO2 in-line
Oximeter (MiniOx I oxygen analyser, Catalyst Research Corporation, Owings Mills, MD, USA) [53]; and
CO-Oximeter 682 (Instrumentation Laboratory, Lexington, MA, USA) [68].
Cardiac output monitors
Vigilance CCO monitor (Edwards Lifesciences, CA, USA) [36, 37]; capnodynamic CO measurement
using Fleisch pneumotachograph (Hans Rudolph Inc., Kansas City, MO, USA) [61]; COM-1
(Baxter-Edwards Critical Care Division, Irvine, CA, USA) [35, 41, 44, 45, 54, 56, 65–67, 72–74, 79];
Monitor 9530 (Baxter-Edwards Critical Care, CA, USA) [53]; and 9520A Cardiac Output Computer
(American Edwards Laboratories, Irvine, CA, USA) [40, 53, 68, 75].
Brain monitors EEG (A1000, Aspect Medical Systems, Yatic, MA, USA) [55].
Blood cell counters WBC (Hemavet, HV950FS, Drew Scientific, Inc., TX, USA) [33, 48].
Protein assay TP assay refractometer (National Instrument, Baltimore, MD, USA) [39, 75].
Colloid osmometers 4100 (Wescor, Logan, UT, USA) and 4420 (Wescor, Logan, UT, USA) [49].
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necessary not only for animal welfare purposes but also
for the proactive minimisation of staff fatigue. A team of
scientists, nurses, veterinarians, intensive care specialists,
surgeons, cardiologists, and perfusionists are present during
commencement of complex experiments and remain on call
for the duration of the experiment. If at any time the animal
becomes physiologically distressed to such an extent that
it cannot be managed or reversed, it will be immediately
euthanized and documented accordingly.
3.1.1. Animal Selection and Preanaesthetic Care. Batches of
healthy adult sheep (Ovis aries) are procured from a breeding
institution and reared as a flock in an open pasture farm.
Sheep sizes are tailored to specific experiments and their
weights are generally in the range of that of a small adult
human [78]. Within two weeks prior to experiments, animals
are transported to and housed at a purpose built animal
facility and managed as per standard operating procedures.
The sheep are fedwith proprietary sheep feed and lucerne and
have free access to water. Shelter is provided in built sheds in
which the sheep have to free access. Shade is provided by large
trees in the paddocks and the sheep interact freely with each
other. In general, animals are fasted overnight with free access
to drinking water until two hours before the procedure. The
sheep are subjected to preexperimental complete veterinary
clinical examinationwhich includes body temperature, pulse,
and respiratory (TPR) parameter checks. The sheep are then
restrained in a sling cage and the ventral aspect of the neck is
shaved to facilitate vascular access.
3.1.2. Anaesthesia Technique. Each study has a different pro-
tocol of maintenance drugs for total intravenous anaesthesia
(TIVA), but the initial induction and instrumentation for
haemodynamic monitoring is essentially identical across
all the studies. The BSD studies form the foundation of
this technique [27]. Under local anaesthesia with ligno-
caine 1%, a 7FG triple-lumen central venous line (Arrow-
Howes, Research Triangle Park, NC, USA) is placed in
the external jugular vein (EJV) of the awake sheep. The
internal jugular vein (IJV) is usually of small calibre and is
often absent in sheep [80]. This catheter is used for initial
blood sampling and for intravenous (IV) administration of
premedication, induction agents, drugs, fluids, and TIVA
throughout the procedure. Following any required baseline
blood sampling, the sheep are administered buprenorphine
(0.01mg/kg) by slow IV injection tominimise distress during
subsequent procedures. For experiments requiring prolonged
cannulation procedures, further sedation with midazolam
is indicated. An 8Fr sheath is placed in the left EJV under
local anaesthesia for subsequent placement of a pulmonary
artery catheter (Edwards Lifesciences, Irvine, CA, USA).
Additional sheathsmay be placed in the opposite EJV to facil-
itate cannulation and intracardiac echocardiography (ICE)
in ovine extracorporeal membrane oxygenation (ECMO)
experiments (Figure 1). General anaesthesia is induced by
intravenous administration of midazolam (0.5mg/kg) and
alfaxalone (3mg/kg) (Alfaxan Anaesthetic Injection, Jurox
Pty Ltd., NSW, Australia). Alfaxalone is given in 4 aliquots
(a)
(b)
(c)
(d)
(e)
(f)
Figure 1: An adult Merino ewe being prepared for venovenous
extracorporeal membrane oxygenation (VV-ECMO). VV-ECMO
is implemented in patients with severe respiratory failure refrac-
tory to conventional ventilatory support to provide gas exchange.
Venous blood from the patient is accessed from large central veins
and returned to the right atrium after it has passed through an
oxygenator. The animal has been restrained in a sling cage (a);
ventral neck hair has been clipped and aseptically prepared to allow
intravenous access to be gained; note the brown colour of povidone
iodine. A multilumen central venous catheter has been inserted
into the left jugular vein of the animal under local anaesthetic and
sutured into place (b) to allow for blood sampling and medications
and fluid administration. The left jugular vein has been further
cannulated with an 8G sheath for the insertion of a pulmonary
artery catheter (c) for haemodynamic monitoring. An 11G sheath
catheter has been inserted proximally into the left jugular vein under
local anaesthetic and sutured into place to allow for intracardiac
echocardiography (ICE) catheter to be inserted (d).The right jugular
vein has been cannulated both proximally (e) and distally (f) with
single lumen central lines to aid subsequent insertion of return
and access ECMO cannulae, respectively. Incremental doses of
midazolam are administered to maintain sheep comfort during the
prolonged procedure.
at 15 s intervals. Anaesthesia is maintained with continu-
ous infusions of alfaxalone (4–6mg/kg/hr), ketamine (3–
5mg/kg/hr), andmidazolam (0.25–0.5mg/kg/hr). Buprenor-
phine 0.01mg/kg is administered intravenously every six
hours throughout the study period for ongoing analgesia.
Anaesthetic drug doses are titrated to maintain an appropri-
ate plane of anaesthesia determined bymonitoring heart rate,
blood pressure, respiratory rate, eyelash reflexes, chewing,
jaw movements, and haemodynamics [81–84]. Gentamicin
240mg and cephalothin 1 g are administered intravenously
for presurgical prophylaxis in lengthy experiments such 24 h
ECMO studies.
Alfaxalone is currently only approved for use in cats
and dogs [85–88]. Animal models such as those that are
being developed for investigation of critical illness result in
significant physiological insult to the experimental subject.
Hypoxia, acidosis, and haemodynamic instability are com-
mon sequelae of the experimental pathological states under
investigation. Consequently, the choice of the anaesthetic
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agent is guided by effective anaesthesia and analgesia and
appropriate surgical conditions. Haemodynamic stability is
an essential consideration. Agents such as inhaled anaes-
thetics or propofol often cause hypotension, which could
interfere with the effect of the insult under investigation.
Alfaxalone provides consistent anaesthetic conditions with
goodhaemodynamic stability [89]. It however continues to be
considerably expensive, leading to significant limitations for
its use in large animals. Addition of ketamine andmidazolam
provides analgesia as well as reducing the requirement of
alfaxalone as a single agent for anaesthesia. To our knowledge,
it is only our studies that have used and continue to use
alfaxalone for induction and maintenance of anaesthesia in
a large number of sheep. We have been very successful with
the combination of alfaxalone, ketamine, midazolam, and
buprenorphine with or without fentanyl for the maintenance
of anaesthesia and analgesia. This approach continues to be
themainstay for TIVA in our experimentswith consistent and
desirable anaesthetic outcomes.
3.1.3. Airway Access and Ventilation. The sheep are intubated
whilst in the sling cage with assistance from animal handlers.
Orotracheal intubation is performed with size 8, 9, or 10
cuffed endotracheal tube, depending on sheep size (Portex;
Smiths Medical, Australia) under direct laryngoscopy and
ventilation with 100% oxygen via an ambu bag. Sheep are
then placed on the surgical table (or into a metabolic
cage depending on the study) in lateral recumbent posi-
tion for further instrumentation. Mechanical ventilation is
commenced using a Galileo intensive care ventilator (Hamil-
ton Medical AG, Switzerland) with a sidestream end-tidal
CO
2
(ETCO
2
) detector (Marquette TRAM, GE Healthcare,
Waukesha, WI, USA). The initial ventilator tidal volume
is set to approximately 10mL/kg with a respiratory rate of
15 breaths/min, positive end expiratory pressure (PEEP) of
5 cmH
2
O, and initial FiO
2
(fraction of inspired oxygen)
of 1.0. These settings are then titrated based on arterial
blood gas (ABG) results. In studies involving models of
acute lung injury, a low tidal volume, high PEEP strategy is
employed to minimise ventilator induced lung injury [90–
92]. In the majority of studies, a tracheostomy is performed
to facilitate bronchoalveolar sampling. This is necessary as
standard bronchoscopes are not of sufficient length to access
segmental bronchi in sheep through an endotracheal tube.
An appropriately sized tracheostomy tube (average size 7–10)
(Portex, Smiths Medical, Australia) is inserted surgically into
the trachea via a 3 cm transverse incision made between two
tracheal rings at approximately 6 tracheal rings distal to the
cricoid cartilage. After securing the airway, the orotracheal
tube is then withdrawn and animals are ventilated through
the tracheostomy tube. An orogastric tube is inserted and the
distal end is sutured to the lower lip and allowed free drainage
or suction to prevent ruminal tympany.
3.1.4. Haemodynamic Monitoring. Detailed reviews of prin-
ciples and practices of haemodynamic monitoring and man-
agement are beyond the scope of this paper; readers are
referred elsewhere [93–98]. The transfacial artery is surgi-
cally exposed and cannulated for invasive blood pressure
monitoring and for ABG sampling. Physiologic variables are
continually monitored with theMarquette Solar 8000 Patient
ICU CCU Monitoring System (GE Healthcare, Waukesha,
WI, USA) and recorded every five seconds with custom soft-
ware. A pulmonary artery catheter (Swan-Ganz CCOmbo,
Edwards Lifesciences, Irvine, CA, USA) is inserted via the
EJV sheath and is coupled with the Vigilance II monitor
(Edwards Lifesciences, Irvine, CA, USA) to record continu-
ous cardiac output (CCO), mixed venous oxygen saturation
(SvO
2
), central venous pressure (CVP), pulmonary artery
pressure (PAP), systemic vascular resistance (SVR), stroke
volume (SV), and core body temperature (BT). Indices
can be corrected for body surface area (BSA) using the
following equation: BSA (m2) = 0.094 (body weight in kg)0.67
[99]. Measured variables are recorded every five seconds
using proprietary software. CVP and PAP measurements are
taken from the respective ports of the Swan-Ganz CCOmbo
catheter. Pulmonary artery occlusion pressure (PAOP) can
also be measured when required. Direct arterial blood pres-
sure (ABP)measurements are taken from the facial artery and
transduced to the Marquette Solar 8000 monitor. Electrocar-
diography (ECG) readings are achieved via an ECG module
and routed to the monitor. The accuracy of any devices such
as those used to measure blood pressure is an important
consideration when selecting monitoring equipment for use
in animals [100]. We routinely measure and monitor direct
ABP and CVP. Monitoring of CVP is useful in measurement
of hydrostatic pressure in the intrathoracic vena cava which
is a useful guide not only in fluid replacement therapy
but also to the ability of the right heart to handle the
venous return [9]. Direct blood pressure measurement is not
without problems; clotting in the catheter can occur; time is
required to instrument the patient; the electronic equipment
is expensive; and potentially fatal complications can occur
[101].
The laboratory is also equippedwith an ultrasonic cardiac
output monitor (USCOM A1, Sydney, NSW, Australia). This
device is used to guide haemodynamic management and to
collect additional haemodynamic data [102, 103]. Depending
on the experiment, transthoracic, epicardiac, or intracardiac
echocardiography may be used in our models for cardiac
function assessment and data collection purposes.
3.1.5. Respiratory Monitoring. Continuous pulse oximetry
(SPO
2
) and ETCO
2
recordings are achieved via couplings to
theMarquette Solar 8000 monitor. Pulse oximetry provides a
measure of oxyhaemoglobin saturation in blood and is one of
the most utilised monitoring aids in the critically ill or emer-
gent patient [7, 9, 10, 104]. Accuracy and failure rates (failure
to produce a reading) vary widely from model to model and
from species to species [105]. We obtain reasonably accurate
ETCO
2
measurements that provide valuable information on
the ventilatory status of the patient [9–11, 104, 106]. ETCO
2
measurement also provides an early warning of serious
hypotension and very low cardiac output from the right
side of the heart and detects apnoea and breathing circuit
6 BioMed Research International
disconnections [10, 106]. Arterial blood samples are collected
from the facial artery at predetermined intervals depending
on the study. ABGs are determined using an automated
analyser (ABL800 Flex Radiometer, Copenhagen, Denmark),
providing readings for arterial partial pressures of O
2
(PaO2)
and carbon dioxide (PaCO2).TheABG analyser also provides
absolute values for oximetry including the concentrations of
total blood haemoglobin (ctHb), oxygen saturation (sO
2
),
fractions of oxyhaemoglobin (FO
2
Hb), carboxyhaemoglobin
(FCOHb), methaemoglobin (FMetHb), deoxyhaemoglobin
(FHHb), and foetal haemoglobin (FHbF). The ABG anal-
yser is used to monitor blood acid-base status (pH), elec-
trolytes (chloride, calcium, potassium, and sodium ions), and
metabolites (blood glucose and lactate). Ventilation data are
recorded on a breath-by-breath basis using inbuilt software
of the Galileo ventilator. Readings of pulmonary static com-
pliance are recorded from the ventilator at predetermined
intervals.
In some animal models, electrical impedance tomog-
raphy (EIT) is used to determine the spatial impedance
distribution in a body cross-section by providing a dynamic,
breath-to-breath measurement of both global and regional
ventilation [107, 108]. EIT monitoring has the potential to
become a noninvasive bedside tool for assessment of regional
lung ventilation and lung recruitment in patients with acute
respiratory failure [107–112].
3.1.6. Microcirculation and Tissue Monitoring. Concomitant
monitoring of the macro- and the microcirculation using
sidestream dark-field (SDF) imaging is often necessary in
studies investigating shock and mechanisms of organ injury.
For example, in the studies that examine the tissue effects of
resuscitation with various fluids and blood products in ovine
models of haemorrhage, trauma, and sepsis, real-time tissue
oxygenation [113–116] ismonitored by the insertion of oxygen
probes (OxyFlow, Optronix, Oxford, UK) into the brain,
heart, renal cortex, liver, and skeletalmuscle. Tissue perfusion
[113–116] is monitored by the insertion of Laser Doppler
Flow probes (MNP100XP orMNP110XP, OxyFlow, Optronix,
Oxford, UK) into the brain, heart, renal cortex, liver, and
skeletal muscle. Tissue metabolism is monitored by the
insertion ofmicrodialysis [117–121] catheters into the anterior
surface of the left ventricle, renal cortex, liver, skeletal muscle,
and the femoral artery. These monitoring techniques are
technically demanding; therefore, standardisation of anaes-
thesia, resuscitation and haemodynamic support practices,
and strict implementation of study protocol are crucial to
procuring quality data. Details of available techniques to
monitor the microcirculation are beyond the scope of this
paper and can be found elsewhere [113–116].
3.1.7. Temperature, Fluid, Vasoactive Drugs, and Electrolyte
Management. Continuous temperature recording is impor-
tant in order to detect hypo- or hyperthermia in a timely
manner and institute corrective measures [122]. Animal
patients lose body heat very rapidly when anaesthetised and
precautions should be taken to avoid this [122, 123]. Tem-
perature is managed using a circulating warm water mattress
attached to either the warm water pump cooler or heater
(Hemotherm, Cincinnati, OH, USA). Maintenance fluids
(compound sodium lactate, Plasma-Lyte 148 Replacement,
dextrose solutions, dextrose/saline solutions, or 0.9% sodium
chloride solution) are delivered intravenously at 38-39∘C and
generally run throughout studies at a rate of 2mL/kg/hr or
at 10mL/kg/hr during surgical interventions. Additional fluid
boluses may be required tomaintain blood pressure (BP) and
CO as both BP andCO are clinically relevant to achievemean
arterial pressure (MAP) > 65mmHg and CO > 3.0 L/min.
Dopamine infusion (1mg/mL preparation) titrated to effect
is utilised as an inotrope if there is evidence of tissue
hypoperfusion despite the fact that normal or elevated SVR
occurs. Noradrenaline infusion (60 𝜇g/mL) is commenced
and titrated to effect if there is a decrease in BP, +/− a
decrease in CO, and a decrease in SVR.These haemodynamic
parameters are a rough guide only and may vary between
experiments depending on the research question for a given
study. In our experience with vasoactive drugs in sheep,
glyceryl trinitrate is associated with poor outcomes. Dobu-
tamine causes profound tachycardia. Adrenaline is given
in very minute doses if required. Hydralazine and sodium
nitroprusside are great in decreasing afterload. Amiodarone
when indicated in the management of dysrhythmias is given
in minute doses by slow infusion as sheep are very prone to
heart block. Maintenance fluids are changed to 5% dextrose
in normal saline if blood glucose drops below 2mmol/L.
Potassium chloride solution infusion is given to achievemea-
sured K+ of 3–5mmol/L at a titrated rate of 5–20mmol/hr
as needed. In case of persistent dysrhythmias, 20mmol of
magnesium sulphate solution is given over 30min. Calcium
chloride makes sheep extremely tachycardiac; therefore, we
give calcium gluconate in 2.2mmol boluses to achieve a mea-
sured Ca2+ above 1mmol/L. Bicarbonate levels are corrected
with sodium bicarbonate infusion if the animal is critically ill
and acidotic depending on the bicarbonate deficiency.
3.1.8. Ovine Blood Collection, Storage, and Transfusion.
Healthy adult sheep permit the collection of a unit of whole
blood (∼400mL) into standard human blood collection bags
[20, 124]. Blood is collected through a venous sheath in
the EJV into Leukotrap WB blood bags (Pall Medical UK),
incubated, leukofiltered, and manually separated into plasma
and packed red blood cells (PRBCs) using a plasma extractor
(Fenwal, Baxter, USA).The PRBCs are resuspended in saline-
adenine-glucose-mannitol (SAG-M) additive solution and
stored at 2–6∘C, while plasma is frozen at −20∘C [124].
Human cross-matching protocols have been modified for
sheep, and our observations have detected 18.2% incom-
patibility between ovine PRBCs (ovPRBCs) and potential
recipient sheep [20, 125]. This highlights the importance of
cross-matching especially in transfusion models [20, 124].
3.1.9. Sample Collection and Processing. An indwelling Foley
urinary catheter is inserted urethrally in ewes and attached to
a urine collection bag formeasurement of urinary output and
to facilitate urine sampling for urinalysis. Blood samples are
taken via the facial arterial line or central venous line only
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and processed for submission to the laboratory or instantly
for blood gas analysis. Bronchoalveolar lavage (BAL) and
exhaled breath condensate samples are taken at time points
determined by the individual studies.
3.1.10. Euthanasia Technique. At completion of experiments,
animals are euthanized with intravenous administration of
sodium pentobarbitone 325mg/mL (Lethabarb, Virbac, Aus-
tralia) at 0.5mL/kg. Death of the animal is confirmed by
the loss of cardiac electrical activity, blood pressure, cardiac
output, and reflex activity.
3.1.11. Postmortem Handling and Disposal. A mid-ventral
sternotomy or lateral thoracotomy (depending on themodel)
and coeliotomy are performed. The organs of interest are
examined in situ before being harvested. Tissue samples for
gene expression analysis are collected in RNAlater solution
(Life Technologies, Thermo Fisher Scientific Inc.) or snap
frozen in liquid nitrogen before being stored at −80∘C.
Histological samples are taken and fixed in formalin for later
processing and staining. The rest of the animal remains are
frozen and stored until being able to be disposed of via high
temperature incineration.
3.2. Animal ICU Equipment and Point-of-Care Technology.
All studies use the same standard setup for advanced haemo-
dynamic monitoring, mechanical ventilation, and fluid ther-
apy (Table 3). Individual studies may require additional
sets of equipment and operating table preparation. Figure 2
depicts the theatre setup for ECMO studies.
An intensive care ventilator (Galileo, Hamilton Medical
AG, Switzerland) is utilised for mechanical ventilation. This
advanced microprocessor controlled intensive care ventilator
offers a full spectrum of capabilities, including invasive, non-
invasive, and advanced ventilationmodes plus tube resistance
compensation. It also allows inhalational delivery of drugs.
The expiratory gas condensate samples are collected via an
accessory attachment for a double surface condenser attached
to a chiller (Digital Temperature Controller model 9102,
PolyScience, IL,USA). Contemporary ventilators are versatile
in that they have multiple modes of pressure or volume
controlled cycles. Ventilator terminology, settings, patient
setup, monitoring, and some of the common complications
associated with mechanical ventilation are beyond the scope
of this paper and readers are referred elsewhere [126]. In the
era of lung-protective mechanical ventilation using limited
tidal volumes, higher respiratory rates are applied to main-
tain adequate minute volume ventilation. Patient-ventilator
dyssynchrony can be a problem during mechanical venti-
lation and can lead to patient discomfort and an increased
work of breathing [126–132]. To minimise patient-ventilator
dyssynchrony, the sheep are ventilated to achieve ETCO
2
below 30mmHg, which inhibits the spontaneous respiratory
drive, therefore avoiding the use of neuromuscular blocking
drugs. Proper interpretation of ventilator waveforms affords
the critical care clinician a better understanding of the
patient’s respiratory function, response to therapy, and causes
of patient-ventilator dyssynchrony [132]. The ventilator also
acts as a ventilation meter, respiratory rate monitor, and
apnoea alarm.
The ABL800 Flex (Radiometer, Copenhagen, Denmark)
analyser is used for blood gas analysis.This analysermeasures
any combination of pH, blood gas, electrolyte, oximetry, and
metabolite parameters. It can measure up to 18 parameters
on the same blood sample. The refrigerated Sigma 2-16PK
(Sigma, Germany) centrifuge is used for spinning blood
and BAL samples for submission to the laboratory. This
centrifuge has the microhaematocrit spinning capabilities
for point-of-care measurement and monitoring of packed
cell volume (PCV). A clinical veterinary refractometer is
used for measuring and monitoring plasma protein and
urine specific gravity. A bronchoscope (Olympus) is used for
examining the trachea and bronchi and for bronchoalveolar
lavage. A large animal laryngoscope is used to facilitate
endotracheal intubation. We utilise the mobile C-arm X-ray
generator with a flat detector (Veradius Neo, Royal Philips
Electronics,TheNetherlands) for radiography or fluoroscopy
to verify placement and migration of invasive catheters and
for experimental data collection as required.
Tissue chemistry analysis is accomplished with patient-
side microdialysis equipment which includes the microdialy-
sis pumps CMA 107 and CMA/102 (CMA Microdialysis AB,
Solna, Sweden) and the point-of-care microdialysis analyser
(ISCUSflex, M Dialysis AB, Solna, Sweden). The ISCUSflex
analyser takes measurements to monitor tissue chemistry
from within microdialysis samples taken from virtually any
tissue or organ in the body. Up to six different metabolites
(glucose, lactate, pyruvate, glycerol, glutamate, and urea are
assayed) provide unique opportunities for early detection of
metabolic crisis and ischemia and for guiding therapeutic
interventions. Tissue oxygenation and blood flow monitors
are used for continuous monitoring. These machines permit
continuous and simultaneous measurement of tissue oxy-
genation, blood flow, and temperature from the same probe
or tissue microregion.
In addition to the traditional measurement of activated
clotting time (ACT) of whole blood at point-of-care with a
cage-side blood clotting system (Hemochron, ITC, NJ, USA),
there are two pieces of equipment for advanced coagulation
studies. These include the rotating pin thromboelastometry
(ROTEM, Tem International GmbH,Munich, Germany) and
the multiple platelet function analyser (Multiplate, Verum
Diagnostica GmbH, Munich, Germany). The ROTEM uses
thromboelastometry to determine if haemorrhage is caused
by surgical bleeding, platelet dysfunction, clotting factor
insufficiency, fibrin insufficiency, or hyperfibrinolysis [133–
138]. The Multiplate uses impedance aggregometry to assess
platelet function in whole blood [139–143].
3.3. Data Capture and Archiving. We have developed novel
techniques for electronic data collection and extraction.
Digital data are collected and saved in a computer hard
drive from the Marquette monitor as 5-second snapshots
of the current values of the variables, the ventilator as
breath-by-breath, the ECMOpump at 5-second intervals, and
haemodynamic data by the Vigilance II at 2-second intervals.
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Table 3: Categories of animal intensive care unit (ICU) theatre devices used in ovine models of critical care research at the Critical Care
Research Group (CCRG) Laboratory.
Continuous monitors Life support Point-of-care technology
Global (i) Fluid pumps (i) Blood gas analysis
(i) Cardiovascular (ECG, ABP, HR, CVP, CCO, and
SvO2)
(ii) Mechanical ventilators (ii) Centrifuges
(ii) Respiratory oxygenation(SPO2), ventilation
(ETCO2 and EIT)
(iii) Patient warming sources (iii) Refractometer
(iii) Core body temperature (iv) Oxygen delivery (iv) Microdialysate analysers
(iv) Neurological monitoring (cEEG) (v) Suction apparatus (v) Multiplatelet function
Regional (vi) ECMO (vi) Rotational thromboelastometry
(i) Tissue oximetry (vii) RRT (vii) Fluoroscopy
(ii) Tissue perfusion (viii) HFOV (viii) Surface and intracardiac echocardiography(USCOM and iCATHe)
(iii) Tissue metabolism (ix) VADs (ix) Renal Doppler
(x) TAH (BiVACOR)
(xi) Inhaled NO therapy
ECG: electrocardiograph; ABP: arterial blood pressure; HR: heart rate; CVP: continuous venous pressure; CCO: continuous cardiac output; SvO2: mixed
venous oxygen saturation; ETCO2: end tidal carbon dioxide partial pressure; EIT: electrical impedance tomography; cEEG: continuous electroencephalogram;
ECMO: extracorporeal membrane oxygenation; RRT: renal replacement therapy; HFOV: high frequency oscillatory ventilation; NO: nitric oxide; USCOM:
ultrasonic cardiac output monitor; iCATHe: intracatheter echocardiography; VADs: ventricular assist devices; TAH: total artificial heart.
Analogue signals, if available, are routed into custom written
software and recorded at an appropriate frequency, often
200Hz or 1 kHz. During data collection, if the original signals
are not optimum, for instance, a poor ECG, a damped ABP,
or the oximeter probe is not attached, then the extracted
data will reflect this as either missing data or incorrect data.
Human error may also play a role especially due to fatigue
or unfamiliarity with patient monitors. The data acquisition
programme may crash and may not restart soon enough for
continuity of the data.
Data are extracted in text form from the files quasi-
automatically using an assortment of purpose written pro-
grammes and macros into proprietary computer spread
sheets. Each study is in a directory based on the date and
time. Automated extraction, albeit practical, can lead to some
glitches; for instance, if a variable is missing or inaccurate at
an exact point, it will be extracted as it is. Data once captured
is prospectively analysed to ensure integrity and quality.
3.4. Synopses of Validated Ovine Models and Related Studies
3.4.1. ECMO Studies. The sheep ECMO model is a mul-
tifaceted study that was designed to investigate alterations
in inflammation and coagulation, drug pharmacokinetics,
ECMO induced organ injury, novel echocardiography tech-
niques, and oxidative stress levels during venovenous (VV)
ECMO [2, 13–15]. The study also seeks to understand the
pathophysiology of ECMO and to determine if the transfu-
sion of aged compared to fresh ovine packed red blood cells
(PRBCs) acts to compound ECMO inflammation leading
to tissue injury. VV-ECMO is a form of extracorporeal
respiratory support, where venous blood is drained from the
patient to a gas exchange device (oxygenator) via cannulae
placed in a large central vein. Blood then becomes enriched
(a)
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Figure 2: Standard animal intensive care unit (ICU) theatre
of the Critical Care Research Group (CCRG). For continuous
haemodynamic monitoring, the Marquette Solar 8000 Patient ICU
CCU Monitoring System (GE Healthcare, Waukesha, WI, USA)
consisting of modules (a), displays (b and c), and processor unit
(d) together with Vigilance II monitor (e) coupled with Swan-Ganz
CCOmbo pulmonary artery catheter (f) (Edwards Lifesciences,
Irvine, CA, USA) are used. Other accessories include the hard
disc (g) for data storage and an analogue to digital data converter
(h). Recruitment of the intensive care ventilator Galileo (Hamilton
Medical AG, Switzerland) (i) is performed with the aid of an
Ohmeda breathing bag (j) before every experiment. Fluids and
medications are delivered from the intravenous fluid workstation
(k). Some experiments require the use of an electrosurgical unit (l)
and echocardiography (m). All animals have bladder catheters and
urine is collected in a sterile bag (n).
with oxygen, has carbon dioxide removed, and is returned to
the right atrium. VV-ECMO is a viable option in critically
ill patients with potentially reversible respiratory failure who
fail conventional treatment. Ongoing refinements in ECMO
technology and clinical delivery may further improve patient
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Figure 3: Sheep on venovenous extracorporeal membrane oxy-
genation (VV-ECMO). Equipment includes the Stryker light source
(a) attached to an Olympus bronchoscope (b) for bronchoscopy
and bronchoalveolar lavage. The Marquette Solar 8000 Patient
ICU CCU Monitoring System (GE Healthcare, Waukesha, WI,
USA) (c) and monitor (d). The Galileo ICU ventilator (e). ECMO
return (f) and access cannulae (b), respectively. The pump assem-
bly consisting of the non-CE marked air-oxygen mixture (FiO
2
)
(Sechrist, Anaheim, CA, USA) (h). CE marked ECMO 550 Bio-
Console Bio-Medicus (Medtronic Bio-Medicus Inc., Eden Prairie,
MN, USA) (i). CEmarked artificial lung (Quadrox PLS) oxygenator
(j). Chest drain (K). Sheep (l). Permanent Life Support (PLS) ECMO
circuit (MAQUET Cardiopulmonary AG, USA) (m). The Rotaflow
Centrifugal Pump and surface coated circuitry, the console pump
speed controller (Medtronic) with external drive head, and the
heating source are not visible.
outcomes. A typical ECMO animal setup is illustrated in
Figure 3.
3.4.2. TRALI Studies. TRALI is considered themost frequent
cause of transfusion-related morbidity and mortality; how-
ever, the mechanism by which it develops remains to be fully
elucidated [76, 125]. Crucial to this is the development of
clinically relevant animal models.Thus, our group developed
the first large animal model of TRALI, using sheep. In
this model, sheep were anaesthetised and instrumented and
then infused with Escherichia coli lipopolysaccharide (LPS)
to simulate bacterial infection, which is one of the risk
factors for the development of TRALI. Sheep were then
given a 10% transfusion with aliquots of pooled supernatant
prepared from date-of-expiry human blood products (either
day 5 platelet units or day 42 PRBC units) to provoke the
development of TRALI. Control sheep received saline as a
control first insult and pooled supernatants from equivalent
fresh (day 1) human blood products as a control second
insult. In this model, as in clinical cases, TRALI was defined
by the development of hypoxaemia (PaO
2
/FiO
2
< 300 on
ABGanalysis) andpulmonary oedema (diagnosed by blinded
histological assessment of postmortem lung sections), and
80% of LPS-treated sheep that were transfused with the date-
of-expiry supernatant developed TRALI. This indicated the
importance of both recipient and blood product factors in
TRALI, providing further evidence of a two-event model
of TRALI pathogenesis. While the incidence of TRALI
was identical between these two groups, the physiological
changes associated with TRALI induced by PRBC super-
natant appeared to be more severe than those induced by
the platelet supernatant, with higher PAP and CVP and
lower CO. Further studies using the ovine TRALI model are
planned to investigate the role that prestorage leucodepletion
of blood products may have upon the development of TRALI
as well as whether specific protein or lipid factors that form
part of the storage lesion of blood products may individually,
or in combination, induce TRALI.
3.4.3. Proteogenomic Studies to Understand Selective Sus-
ceptibility to Endotoxin. During later TRALI experiments,
Chemonges and colleagues [144] observed that “some sheep
were more susceptible to the effects of LPS than others
from the same mob. As a result, the more susceptible sheep
required considerably less LPS to prime their immune sys-
tem. It is not known why this observation occurred, despite
the sheep being the same breed, with similar characteristics.
This striking observation of differential susceptibility to
LPS has prompted new studies that are seeking to explain
the variation” by way of proteogenomic characterisation of
circulating acute phase markers and their bioassay devel-
opment in sheep. This seed study is designed to charac-
terise the selective resistance to the effects of endotoxin; to
understand the role of genetic traits, molecular mechanisms,
and products associated with the selective susceptibility to
endotoxin during priming of the immune system; and to
develop comprehensive acute phase protein and circulating
microRNA profiles in sheep exposed to endotoxin [144].
3.4.4. CRASH-Sepsis and CRASH-Haemorrhage Studies.
These studies are investigating the effects of trauma,
haemorrhage, and infection on various tissue beds.
In addition, the effects of resuscitation with various
intravenous fluids and fresh and stored blood are also
being investigated [20]. These models will provide ideal
platforms for investigating the interactions between macro-
and microcirculation and the effects of various resuscitation
targets and techniques on tissue homeostasis. These studies
utilise holistic tissue monitoring that includes tissue
chemistry analysis, tissue oxygenation, and perfusion
measurement using techniques described in earlier sections.
3.4.5. Studies on Acute Smoke Inhalation Lung Injury. Pul-
monary injury from acute smoke inhalation is a major
cause of morbidity and mortality in burns patients [144].
The validated S-ALI model [25] has been very useful in
investigating many areas of lung injury and acute respiratory
distress syndrome (ARDS) and in understanding the basis
of management of lung injury [145]. This model has been
used successfully in many experiments such as ovine ECMO
and investigations into the management of inhalational lung
injury (Figure 4). One of such studies aimed to analyse the
effects of nebulising an amphoteric, hypertonic chelating
agent for pulmonary decontamination immediately following
a standard smoke inhalation injury. It showed a promising
treatment strategy for victims of smoke inhalation using an
inhalation injury model [25].
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Figure 4: Ovine model of smoke inhalation injury. Nebulisation
in a conscious sheep (a) in standing position following smoke
inhalation via tracheostomy. Anaesthesia was induced using propo-
fol 4mg/kg IV and maintained with continuous infusion of mida-
zolam 0.7mg/kg/hr IV and ketamine 8mg/kg/hr IV to facilitate
instrumentation before allowing the sheep to recover. The right
facial artery was cannulated to facilitate continuous arterial blood
pressure monitoring and serial arterial blood gas analysis (b).
Diphoterine or saline was placed in the nebuliser (c) and the sheep
had free access to food (d). A Swan-Ganz pulmonary artery catheter
(e) was inserted for continuous monitoring of pulmonary artery
pressure, central venous pressure, and continuous cardiac output
using thermodilution technique.The animal was ventilated through
an open surgical tracheostomy (f).The crush (g) prevented the sheep
from making large movements that could dislodge the attached
instruments. Animals were monitored for up to 21 hours following
instrumentation before being sacrificed.
3.4.6. The Ovine Brain Stem Death (BSD). The sheep BSD
model provides a tool for the investigation of a wide array of
mediators and also the effect of brain stem death on many
organs [26, 27]. Brain death causes significant physiologic
stress that injures transplantable organs. This reduces the
number of transplantable organs, increases posttransplant
dysfunction, and contributes to rejection. Large animal
models are required to further study pathologic mecha-
nisms contributing to the insult seen in these organs as
other current models are of short duration and do not
reflect clinical reality. Studies that developed a clinically
relevant large animal model of brain death using sheep and
investigated the physiological responses that occur over 24
hours have been completed (unpublished data). After initial
cannulation and anaesthesia using the techniques described
above, an intracranial burr hole was established for insertion
of an intracranial pressure monitoring device. For animals
randomised to brain death, another cranial burr hole was
made and an extradural foley catheter was inserted. This
was inflated with 20–30mL saline to reproduce a rapidly
expanding intracranial lesion leading to brain hypoperfusion
and brain death. Appropriateness of volume was additionally
assessed by further inflation of small aliquots (1mL) saline
into the catheter until the point that no further sympathetic
response was obtained. Intracranial pressure was maintained
above the mean arterial pressure for 30min. The criteria
used for ascertaining the establishment of BSD were negative
cerebral perfusion pressure for 30min, loss of corneal and
papillary reflexes, and no cough on bronchoscopy. Ketamine
and alfaxalone were reduced to 2mg/hr and 1mg/hr after the
diagnosis of brain death.Midazolamwas ceased if it had been
used.The animalswere thenmaintained for 24 hours at which
point they were sacrificed. The sheep received care similar
to a human donor, including vasopressors, inotropes, and
hormonal therapy [26, 27]. The brain dead animals displayed
significant elevations in heart rate, mean arterial pressure,
and cardiac index on induction of brain death. Physiologic
data has demonstrated that pulmonary pressure signifi-
cantly increased after brain death and remained elevated
for 24 hours. This may contribute to cardiac injury and the
right ventricular dysfunction seen after transplantation. This
model has been used to investigate the effect of an endothelin
antagonist drug on preservation of the cardiopulmonary
function following brain death [27]. Studies such as this have
the potential to develop techniques to improve the availability
and quality of donor organs for transplantation [27].
3.4.7. BiVACOR and BiVAD Artificial Heart and the Ovine
Left Ventricular Assist Device (LVAD). BiVACOR is a novel
rotary total artificial heart which is being developed in part
by our group to treat global end-stage heart failure [21–23].
Studies are ongoing and preclinical prototypes have been
tested by our group on an ovine model for the artificial heart.
Our studies have assessed the haemodynamic performance
of the dual pumping device during biventricular assistance
(BiVAD) and total artificial heart (TAH) support, whilst
assessing the ability to simultaneously alter the left/right heart
chamber outflows successfully. We have also assessed the use
of dual rotary LVAD systems to provide biventricular sup-
port. In these studies, haemodynamic and pump parameters
were captured at 100Hz using a dSPACE acquisition system
(DS1103, dSPACE, MI, USA). Systemic and pulmonary flow
ratesweremeasured using clamponperivascular flow sensors
(MC20PAU, Transonic Systems, NY, USA) connected to a
perivascular flow meter (T402-PP, Transonic Systems, NY,
USA). Circulatory and pump pressures were recorded using
silicon-based transducers (PX181B-015C5V, Omega Engi-
neering, CT, USA). Figure 5 shows an anaesthetised sheep
with a median sternotomy being prepared for artificial heart
implant studies.
3.4.8. Studies to Assess Cerebral Microcirculation. The aim of
this model is to describe a novel transseptal catheterisation
technique for the injection of colour-coded microspheres for
the assessment of cerebral microcirculation [28]. Transseptal
catheterization refers to the intracardiac puncture of the
interatrial septum with the intention of accessing the left
atrium from the right atrium, by a technique originally
developed by Ross [146]. The targeted area in a transseptal
catheterization is the fossa ovalis (FO), as it is the thinnest
region within the septum. Guidance of the procedure as well
as identification of the FO is facilitated by fluoroscopy [147]
and ultrasonography [148]. After insertion of the transseptal
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Figure 5: Implanting an artificial heart in an ovinemodel.This study
evaluated a biventricular mechanical device called BiVACOR that
is being developed for patients with end stage heart failure. Sheep
are anaesthetised and maintained as in humans undergoing cardiac
transplantation. In this sheep model, anaesthesia is maintained by
constant infusion of propofol and fentanyl.The approach to the heart
is via a median sternotomy. Anastomoses to prosthetic blood vessels
are created on the pulmonary vein (a) and artery (b) and dorsal
aorta and clamped for subsequent attachment to the BiVACOR
system (not pictured). In our completed trials, we attached grafts
via an end-to-end anastomosis to the ascending aorta (16–18mm)
and pulmonary artery (20mm) for left and right pump outflows,
respectively. Inflow connections were achieved by removing the
ventricles just below the atrioventricular groove (leaving about 1 cm
of ventricular tissue) and suturing 38mm grafts (end-to-end) to
the ventricular tissue. All grafts were then attached to the pump.
Blood flow after the prosthetic heart implant can be monitored by
flow meters via probes (c). The surgical exposure of the chest cavity
is maintained by a retractor (d) to visualise all organs. The right
lung (e), diaphragm, and heart (h) are visible. A stay suture (g)
facilitates the suspension of major blood vessels during dissection.
Intravenous access for fluid administration was facilitated via a large
bore catheter (i). Note the white colour of propofol (j) being used
to maintain anaesthesia. During dissection and prior to the removal
of the ventricles, continuous haemodynamicmonitoring is achieved
via the Swan-Ganz pulmonary artery catheter (k).
catheter and confirmation of its correct positioning, 4 mil-
lion colour-coded spheres of 15-micron diameter each are
injected hourly (E-Z TRAC; Interactive Medical Technology,
Los Angeles, CA) as previously described [149]. Randomly
assigned colours are attributed to each injection time in order
to minimise selection biases, as previously described [65,
150]. The distribution of the microspheres in brain tissue can
then be determined by cytometry in specific laboratories.The
novelty of this technique is that cerebral blood flow changes
can be assessed over time, as each different colour assigned to
a specific time point will be differentiated during count.
4. Discussion
This paper is probably the first to document the varied anaes-
thetic and data collection techniques, monitoring devices,
and point-of-care instruments utilised in ovine biomedical
research.The disparity in techniques is probably due to study
specific requirements, familiarity of use, and availability of
equipment in specific research settings. Also, in some reports,
little information is published about the monitoring and the
fate of the animal model, which leaves information gaps,
therefore limiting the understanding of the reproducibility
or translatability of those studies. The latter prompted us to
present the practices used by our research group, describing
animal ICU monitoring practices as a model for ovine
biomedical studies. Meticulous monitoring of anaesthetised
animals is essential as failure to detect warning signs of
impending disaster results in a dead or impaired animal
[151, 152].
Our studies are important in that complex and vali-
dated ovine models may, to some extent, be comparable
to other animal models such as swine that can generate
robust mechanistic data that lend themselves to translational
research. While each animal model has significant benefits in
medical research, none is without weaknesses [153]. There is
a dissenting debate that animal-based research is unable to
predict human response because animals and humans have
different evolutionary trajectories [58]. The alternative view
is that animal models should be genetically closer to those
of humans to be relevant [59]. Another potential obstacle
in the use of sheep in whole animal experiments is that
studies that enrol large animals can provoke intense scrutiny
from regulatory oversight groups and journal editors, if not
meticulously designed to address animal welfare concerns.
Current animal ethics requirements emphasise the principle
of replacement, refinement, and reduction (3Rs) in research
using animals based on established guidelines [154]. Our
studies showcase the 3Rs by utilising rational study design
that maximises the research opportunities in a given animal
without compromising quality, using advances in technology
and highly skilled personnel to minimise experimental attri-
tion due to the unexpected loss of experimental animals.
Monitoring devices come in different varieties and can
provide misleading information if they do not function
correctly or are not properly configured. Artefacts do occur,
thus underscoring the necessity for a clinician to physically
check the animal first before assuming the instrument is
faulty [7]. There is no device that replaces a trained per-
son in monitoring an anaesthetised or even a conscious
experimental animal.The studies whosemonitoringmethods
are described here are multifaceted, expensive, and highly
refined. They require meticulous planning, animal prepa-
ration, anaesthesia induction and maintenance, advanced
physiologic monitoring, state-of-the-art data capture, point-
of-care technology, and animal aftercare. This level of mon-
itoring has worked successfully at the CCRG Laboratory;
however, it may not always be possible to be used elsewhere.
Different research establishments have different logistical
constraints and perhaps have different goals with their exper-
iments. It comes at a significant cost and is usually only
possible in large establishments with appropriate research
support and trained personnel. Electronic patient monitors
require regular calibration, require software and hardware
updating, can rapidly become obsolete, and can represent a
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significant financial investment. Also, the majority of devices
available for monitoring animals were manufactured for use
in humans, which may not necessarily be suitable for use
in animals. Information on the description of the strengths,
weaknesses, and rationale of each monitoring device relating
to their use in sheep is still lacking. Moreover, there is no
formal standard to act as a benchmark that evaluates the
diverse equipment available for use in large animal ICUs.This
in turnmay influence investigators to only use or recommend
the type of equipment available in their particular institution
without consideration of the many other options available in
the market.
The full use of the available patient monitoring tech-
nology together with the extraction and archiving of con-
siderable amounts of physiological data from every experi-
mental animal has positive animal ethics implications. This
ultimately minimises the need for repeat experiments by
reducing animal numbers used for experiments and archived
and reproducible information allows for a more effective
transfer of knowledge to others involved in this area of
research.
5. Conclusions
There are significant alternative approaches to anaesthesia
and monitoring of ovine models, probably due to varied
experimental goals. Considerable resource investment in
technology is necessary to satisfy the needs of monitoring
anaesthetised large animals to facilitate the gathering of
robust and translatable research data. The experience of the
professional and technical personnel equates to the equip-
ment being utilised to their maximum capabilities for cutting
edge animal research. Negligible deleterious outcomes when
using ovine models are a result of familiarity and using a
standardised approach to all aspects of animal care.This level
of standard enables the understanding of emerging research
tools such as proteogenomics and other new biomedical
technologies in a laboratory setting, which highlights the
importance of the utilisation of sheep in researching human
disease. We have described a critical care setup with multiple
ovine models enabling the study of very important aspects
for the whole body animal experiments that could provide an
alternative to other large animal models such as pigs.
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